"A pilot study on comparative analysis of minimum inhibitory concentrat" by Krishnan Selvi, A. V. Kavitha et al.
 

A pilot study on comparative analysis of minimum inhibitory concentration and mutant prevention concentration of conjunctival bacterial isolates against fluoroquinolones

Document Type

Article

Publication Title

Indian Journal of Microbiology Research

Abstract

Background: The aim of this study was to compare the Minimum Inhibitory Concentration (MIC) and Mutant Prevention Concentration (MPC) of fluoroquinolones, including ciprofloxacin, moxifloxacin, and gatifloxacin, against Staphylococcus aureus and coagulase-negative Staphylococci (CONS) isolated from conjunctival swabs. Materials and Methods: 25 isolates of Staphylococcus spp., obtained from conjunctival swabs submitted to the Department of Microbiology, Vision Research Foundation, Sankara Nethralaya, were included in this study. The identification and confirmation of Staphylococcus spp. were performed using standard microbiological techniques. The MIC and MPC were determined using the agar dilution method, following protocols from previous studies. The MIC50, MIC90, MPC50, and MPC90 values for the above three fluoroquinolones were calculated and analysed. Results: Out of all 25 isolates, 20 were CONS and 5 were Staphylococcus aureus. In our study, gatifloxacin had least MIC and MPC values when compared to ciprofloxacin and moxifloxacin of gatifloxacin had lower MPC50 and MPC90 values in comparison to ciprofloxacin and moxifloxacin. Our study shows that Gatifloxacin had least MIC and MPC values when compared to ciprofloxacin and moxifloxacin. Besides, MPC of ciprofloxacin, moxifloxacin and gatifloxacin showed wider range of distribution than the MIC. Conclusion: Gatifloxacin demonstrated effective inhibition of resistant mutant strains at lower concentrations compared to ciprofloxacin and moxifloxacin. Additionally, future studies with a larger number of isolates, incorporating pharmacokinetic and pharmacodynamic parameters, will provide essential information on therapeutic outcomes and resistance prevention.

First Page

180

Last Page

185

DOI

10.18231/j.ijmr.2024.033

Publication Date

1-1-2024

This document is currently not available here.

Share

COinS